Status:

COMPLETED

Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies

Lead Sponsor:

Washington University School of Medicine

Collaborating Sponsors:

Brain & Behavior Research Foundation

Conditions:

Depressive Disorder, Major

Depressive Disorder, Treatment-Resistant

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

The purpose of the study aims to determine whether different concentrations of nitrous oxide (N2O) have different antidepressant effects for adults with treatment-resistant major depression.

Detailed Description

Most clinical major depression responds to standard treatments (medication and psychotherapy); however, a significant subset of depressed patients (15-20%) do not respond to these treatments and are r...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Adults 18-75 years of age;
  • Current diagnosis of unipolar major depressive disorder (MDD) without psychosis as confirmed by structured clinical interview for DSM-IV disorders;
  • A score of \>= 9 on the Montgomery-Åsberg Depression Rating Scale (MADRS);
  • Documented (i.e., chart review) lifetime failure to respond to \>=3 adequate dose/duration antidepressant treatment trials, ≥1 medication failure in the current depressive episode;
  • Good command of the English language.
  • Exclusion Criteria
  • Meets criteria for any DSM-IV diagnosis for schizophrenia, bipolar, schizoaffective, obsessive-compulsive, personality, or panic disorders;
  • Any recent (within past 12 months) history of substance dependence or abuse (except tobacco), determined by reported history or urine drug screen;
  • Ability to become pregnant and not using effective contraception;
  • Contraindication against the use of nitrous oxide:
  • Pneumothorax
  • Bowel obstruction
  • Middle ear occlusion
  • Elevated intracranial pressure
  • Chronic cobalamin and/or folate deficiency treated with folic acid or vitamin B12
  • Pregnant patients
  • Breastfeeding women
  • Inability to provide informed consent;
  • Any other factor that in the investigators' judgment may affect patient safety or compliance

Exclusion

    Key Trial Info

    Start Date :

    November 22 2016

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    February 18 2020

    Estimated Enrollment :

    24 Patients enrolled

    Trial Details

    Trial ID

    NCT03283670

    Start Date

    November 22 2016

    End Date

    February 18 2020

    Last Update

    April 4 2022

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Washington University School of Medicine

    St Louis, Missouri, United States, 63110